CREBBP and ovarian carcinoma: In novel identified CNV events of OCCC, CREBBP is involved in tumorigenesis in various cancers, and knockdown CREBBP can promote chemo-sensitivity in ovarian cancer cells (Hu et al., 2021), while EPHA2 is associated with platinum-resistant in HGSOC, and RSK inhibitors effectively sensitized cells with EphA2high to the therapy-induced apoptosis (Moyano-Galceran et al., 2020), LRP1B can act as a predictor of response to pegylated liposomal doxorubicin for ovary cancer (Dionisio de Sousa et al., 2021).